| |
Protea Biosciences, Inc. is a new Biotechnology company, based in Morgantown,
West Virginia, that has been founded to advance and commercialize new Proteomics
technology, under development at the West Virginia University Health Sciences
Center (WVU).
The Company was incorporated in July, 2001
The Founders of the company include a team of leading researchers at the West
Virginia University Health Sciences Center, and Stephen Turner, General Partner
of Origins LLC. Protea’s Scientific Advisors
are as follows:
| John
Barnett, PhD. – |
Professor and Chairman of the
Department of
Microbiology, Immunology and Cell Biology, WVU. Dr. Barnett has an extensive
background in the fields of immunology and immune responsiveness (signal
transduction cascades).
|
|
Barbara Ducatman, M.D. – |
Professor and Chairman of the
Department of Pathology,
WVU School of Medicine.
|
|
Daniel Flynn, PhD. – |
Associate Professor of
Microbiology, Immunology and Cell Biology, and Associate Director for Basic Research, the Mary Babb
Randolph Cancer Center, WVUHSC. Dr. Flynn is
responsible for the cell
signaling research program.
|
| Aaron
Timperman, PhD. – |
Assistant Professor of Chemisty.
Dr. Timperman came to WVU from the University of Washington Department of
Molecular Biotechnology, and
specializes in the development and application of microfluidics technology
to Proteomics.
|
|
William Wardell, M.D., Ph.D. – |
Formerly Senior Vice President,
Drug Development, Parke-Davis,
and a Merck International Fellow
in Clinical Pharmacology.
|
In Partnership with the WVU Core Proteomics
Laboratory, the company is undertaking
the discovery of novel cellular proteins to identify new targets for drug and
assay development. Initially, the primary disease focus is Cancer; however, the
company anticipates that proteomic opportunities in many therapeutic areas will be
identified.
|
|